What Gauge Needle Should Be Used for an IM Injection?

For most adult intramuscular (IM) injections, a 22- to 25-gauge needle is standard, with 22 or 23 gauge being the most common for routine medications and vaccines. But gauge is only half the equation. Needle length, which is chosen separately from gauge, matters just as much for getting the medication into muscle rather than fat. The right combination depends on the injection site, the patient’s body size, and what is actually being injected.

What “Gauge” Actually Means and Why It Matters

Gauge is a measure of the needle’s outer diameter, and the numbering runs in the opposite direction from what you might expect: a higher gauge number means a thinner needle. A 21-gauge needle has a wider bore than a 25-gauge needle. For IM injections in adults, needles in the 22- to 25-gauge range strike a balance between being thin enough to limit discomfort and wide enough to let the medication flow through without excessive force.

The physics behind this are straightforward. Injection force increases steeply as the needle’s inner diameter shrinks, because resistance to flow scales with the fourth power of the needle’s radius.

¹ That means going from a 22-gauge to a 27-gauge needle doesn’t just make things slightly harder to push; it can make injecting a thick medication feel like squeezing toothpaste through a coffee straw. This is why viscous medications like certain antibiotics, hormones in oil-based carriers, and some long-acting antipsychotics typically call for a 21- or 22-gauge needle, while thinner aqueous solutions and most vaccines work fine through a 23- or 25-gauge.

Gauge vs. Length Are Separate Decisions

One of the most common points of confusion is conflating gauge with length. They are independent choices. A 25-gauge needle can come in lengths of 16 mm, 25 mm, or 38 mm. When clinicians talk about choosing the “right needle” for an IM injection, they are really making two decisions at once: how wide (gauge) and how long (in inches or millimeters). Gauge primarily affects pain, flow rate, and tissue trauma. Length primarily determines whether the medication actually reaches the muscle.

A randomized controlled trial in infants receiving vaccines compared needles of different gauges at the same length and found that needle length, not gauge, was the factor associated with fewer local reactions like redness and swelling. Switching between 23-gauge and 25-gauge needles at the same 25 mm length made little measurable difference in reactogenicity.

²

This finding reinforces that while gauge gets a lot of attention from patients worried about pain, length is the variable that most affects whether the injection does its job.

Choosing the Right Length by Injection Site

Standard IM injection sites each have different depths of overlying tissue, so length recommendations vary by location.

• Deltoid (upper arm): Most adults receive a 25 mm (1-inch) needle. This is the default for most vaccines. However, a systematic review of ultrasound measurements of skin-to-deltoid-muscle depth found that some patients in nearly every body mass index category except underweight may need needles longer than 25 mm to reliably reach the muscle. Women and people with higher BMI were most likely to have thicker subcutaneous tissue at the deltoid.
³
• Ventrogluteal and dorsogluteal (hip/buttock): These sites are used for larger-volume injections and typically require a 38 mm (1.5-inch) needle for adults, especially at normal weight or above. For obese individuals, even 38 mm may be marginal at these sites, and clinician assessment is recommended.
⁴
• Vastus lateralis (outer thigh): This site is especially common for infants and self-administered injections. Needle length varies from 16 mm in small infants to 25 mm in older children and lean adults, with longer needles for larger individuals.

How Body Size Changes the Calculation

Body weight, sex, and BMI are the biggest variables that should influence needle length, and to a lesser extent, gauge. The concern is that using a needle that is too short for someone’s body size will deposit the medication into subcutaneous fat instead of muscle. This is not just a theoretical worry: subcutaneous deposition can alter how quickly a drug is absorbed, affect vaccine immunogenicity, and increase the risk of local reactions.

A study using statistical modeling of deltoid fat thickness found that a standard 1-inch needle reached the deltoid muscle in about 99 percent of men under 260 pounds but only about 85 percent of women under 200 pounds. For people above those weight thresholds, even a 1.5-inch needle failed to reach muscle in roughly a quarter of cases. The odds of an inadvertent subcutaneous injection in heavier patients were more than four times higher than in those below the weight cutoffs.

⁵

A combined analysis of New Zealand data found that the arm circumference at which a longer deltoid needle becomes necessary differs substantially between men and women. For a 25 mm depth cutoff, the arm circumference thresholds were about 40 cm for men and about 37 cm for women. BMI cutoffs showed a similar sex difference, with women needing a longer needle at a lower BMI.

⁶

The practical takeaway: if you are administering or receiving an IM injection and the patient is a woman with a BMI above about 30 or a man with a BMI above about 38, a 25 mm needle in the deltoid may not be long enough. Switching to a 38 mm (1.5-inch) needle or selecting a different injection site with less overlying fat can help ensure the medication gets where it needs to go. Current guidelines generally recommend assessing body habitus rather than using a one-size-fits-all needle.

What Happens at the Gluteal Sites in Heavier Patients

The gluteal region carries more subcutaneous fat than the deltoid in most people, which is why gluteal IM injections default to a 38 mm needle. For obese individuals, a 38 mm needle is the minimum, and some clinicians use even longer needles depending on the patient’s build.

⁴

Cadaveric research has also highlighted that fat distribution at gluteal sites varies across populations and between the ventrogluteal and dorsogluteal locations. In some ethnic groups, particularly in the Asia-Pacific region, subcutaneous fat can be thicker at the ventrogluteal site than the dorsogluteal, which runs counter to the general Western clinical teaching that ventrogluteal is always preferred because it has less overlying fat.

⁷

This is a good example of why blanket injection-site recommendations can be imperfect. A clinician who visually and manually assesses the tissue before choosing a site and needle length will get better results than one who follows a protocol by rote.

Pediatric Needles

Children, especially infants, have much less muscle mass and subcutaneous tissue than adults, so shorter, sometimes narrower needles are appropriate. Infant vaccinations in the anterolateral thigh are commonly given with a 25-gauge, 25 mm needle or a 25-gauge, 16 mm needle, with the skin stretched flat and the needle inserted at a 90-degree angle up to the hub.

⁸

For older children and adolescents, the deltoid site becomes more common, and needle length increases toward the adult 25 mm standard. Gauge stays in the 23- to 25-gauge range for most childhood vaccines. The key concern with pediatric injections is that too-short a needle leads to subcutaneous deposition (which can increase local reactions), while too-long a needle in a small infant could reach bone. In practice, the 16 mm to 25 mm range covers the vast majority of healthy infants and children.

Does a Thinner Needle Actually Hurt Less?

Patients almost universally believe that a thinner needle will mean less pain, and there is some evidence to support the intuition, though the effect is smaller than most people assume. In a study comparing 21-gauge, 23-gauge, and 27-gauge needles during lidocaine injection, participants reported the thinnest needle as least painful more often, and average pain scores were slightly lower with the 27-gauge needle.

⁹

However, the actual numerical differences in pain scores were modest: mean visual analog scale scores ranged from about 16 out of 100 for the thinnest needle to about 19 for the thickest. That is a gap many people would not notice in practice.

Other studies have found even less of a difference. A trial comparing 22-gauge and 25-gauge needles during lumbar epidural injections found no significant difference in pain scores at initial needle entry.

¹⁰

And a randomized trial of trigger-point injections in the trapezius muscle, comparing three needle sizes, found no significant difference in pain intensity during the injection itself.

¹¹

The reality is that most of the pain from an IM injection comes from factors other than the needle’s diameter: the volume of fluid being injected, the medication’s chemical irritation of tissue, the speed of injection, and whether the needle hit a nerve ending. Gauge matters at the extremes (an 18-gauge needle will hurt more than a 25-gauge), but across the 22- to 25-gauge range typically used for IM injections, the difference in pain is often negligible.

Viscous Medications and the Gauge Trade-Off

Some IM medications are simply too thick to push through a thin needle at a reasonable speed. Oil-based hormone preparations, long-acting injectable antipsychotics, certain antibiotics like benzathine penicillin, and concentrated biopharmaceuticals all require wider-bore needles. Trying to force a viscous solution through a 25-gauge needle means the person administering it has to push much harder on the plunger, which slows the injection, increases hand fatigue, and can make the injection jerkier and more uncomfortable for the patient.

Newer needle designs are trying to split the difference. Tapered needles, which start wider at the hub and narrow toward the tip, can reduce injection force for viscous solutions while keeping the puncture point thin. Testing of a tapered 29-gauge needle found that it required less injection force than a standard 29-gauge thin-wall needle for all solutions tested, and performed as well as or better than a standard 27-gauge needle for protein-based biopharmaceutical solutions.

¹²

These innovations are mostly relevant to prefilled syringes used for subcutaneous biologics right now, but the engineering principles apply to IM injection technology as well.

Epinephrine Auto-Injectors and Fixed-Needle Devices

Auto-injectors present a unique challenge because the patient has no choice about gauge or length: the device comes with a fixed needle. Epinephrine auto-injectors on the market use needle lengths ranging from about 12 mm to 25 mm, depending on the brand and whether the device is designed for adults or children.

¹³

The concern cuts both ways. In very obese patients, the fixed needle may be too short to reach muscle through the thigh’s subcutaneous fat, meaning the epinephrine deposits subcutaneously and absorbs more slowly during an emergency. In very thin or pediatric patients, the needle may be long enough to reach bone. Compression of soft tissue during the press-and-hold action of an auto-injector also complicates things: pressing the device firmly against the thigh displaces some fat, effectively shortening the distance the needle needs to travel. Factors like BMI, the force of application, and individual fat distribution all affect whether the drug actually reaches muscle.

Technique Details That Interact with Needle Choice

Even a perfectly chosen gauge and length can fail if the injection technique is off. Stretching the skin flat (rather than bunching it up) before inserting the needle reduces the effective distance to muscle. Inserting at a 90-degree angle maximizes depth. These techniques are standard teaching for IM injections and become especially important when needle length is borderline for a patient’s body size.

The Z-track technique, where the clinician pulls the skin and subcutaneous tissue laterally before inserting the needle and releases it after withdrawal, is commonly taught for IM injections. A study of this method with intramuscular diclofenac found that it reduced drug leakage at the injection site, though it did not significantly affect pain.

¹⁴

Drug leakage matters because it represents a portion of the dose that never reaches the muscle, which can reduce the medication’s effectiveness and cause skin irritation.

When Patients Are Afraid of Needles

Needle phobia is more common than many healthcare providers realize, and it directly influences patient compliance with IM medications and vaccines. A large international survey found that smaller needles were identified by over 90 percent of respondents as a potential solution to alleviate needle fear, and about a third ranked smaller needles as the single most helpful device-related change.

¹⁵

This creates a practical tension. The patient wants the thinnest, shortest needle possible. The clinician needs a needle that actually reaches the muscle and lets the medication flow. For routine vaccines, this tension is usually manageable: a 25-gauge, 25 mm needle is thin enough to be well tolerated and long enough for most adult deltoid injections. For thicker medications that genuinely need a 21- or 22-gauge needle, the best the clinician can do is use good technique, inject slowly, and give the patient warning and distraction rather than switching to a needle too thin for the medication.

Quick-Reference Defaults for Common IM Scenarios

While individual assessment is always important, the following are widely used starting points:

• Adult vaccine, deltoid: 22- to 25-gauge, 25 mm (1 inch). Move to 38 mm (1.5 inch) for heavier patients, particularly women over 200 lbs or men over 260 lbs.
• Adult gluteal IM injection: 21- to 23-gauge, 38 mm (1.5 inch). May need longer for obese patients.
• Viscous medication (oil-based hormone, long-acting antipsychotic): 20- to 22-gauge, with length chosen by site and body habitus.
• Infant thigh vaccination: 25-gauge, 16 to 25 mm depending on age and size.
• Older child or adolescent, deltoid: 23- to 25-gauge, 25 mm.

These are starting points. The consistent message from the research is that clinicians should assess each patient rather than relying on universal defaults, especially at the extremes of body size. Current clinical guidelines acknowledge that the evidence base is not strong enough to set absolute needle-length cutoffs based on demographics alone, and individual assessment remains the recommended approach.

³